Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2024-12-09 Investor Presentation
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Presentation: Phase 2 study of SNT-5505 in myelofibrosis 20 pages 1.6MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation of interim clinical trial data for a drug candidate (SNT-5505) in a Phase 2a trial for myelofibrosis, presented at the 66th American Society of Hematology (ASH) annual meeting in December 2024. It includes extensive clinical trial design, patient characteristics, safety data, symptom scores, and efficacy endpoints. The document is about interim results and clinical data rather than a formal financial report or regulatory filing. It is not an earnings release, annual report, or audit report. It is also not a regulatory announcement, management change, or legal proceeding. The content and format align with an Investor Presentation focused on clinical and strategic information for investors and stakeholders. The length (15,000 characters) and detailed data support this classification rather than a brief announcement or report publication notice.
2024-12-09 English
Change in substantial holding 4 pages 188.5KB
Regulatory Filings
2024-12-03 English
Pause in Trading 1 page 117.6KB
Regulatory Filings Classification · 95% confidence The document is a short market release announcing a temporary pause in trading of the company's securities. It is a brief regulatory announcement without financial data, report content, or detailed analysis. It does not fit into categories like financial reports, management information, or capital updates. It is a regulatory announcement related to trading status, best classified under Regulatory Filings (RNS).
2024-12-03 English
Response to ASX Price Query 5 pages 1.1MB
Regulatory Filings Classification · 95% confidence The document is a correspondence between Syntara Limited and ASX Compliance regarding a price query related to recent trading activity in Syntara's securities. It discusses whether Syntara is aware of any undisclosed information that could explain the trading, references Listing Rules 3.1 and 3.1A, and details the company's response about the confidentiality and upcoming release of interim clinical trial data at a scientific meeting. The document is a regulatory compliance response to a market query rather than a financial report, earnings release, or presentation. It does not contain financial statements or detailed financial data but is a formal regulatory filing responding to ASX's request for information. Therefore, it fits best under Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive regulatory compliance communication.
2024-12-03 English
Notification regarding unquoted securities - SNT 6 pages 18.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme by Syntara Limited. It includes specifics such as the number of securities issued, dates, and mentions shareholder approval under listing rules. The content focuses on the issuance of securities and changes in capital structure rather than financial results or management commentary. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. The document is about the notification of new securities issued, not a full financial report or an announcement of a report publication. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2024-11-28 English
Change of Director's Interest Notice - GP 2 pages 545.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares and options held before and after the change, nature of the change, and confirms no trading during a closed period without clearance. This is a clear report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is 3641 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the correct classification is Director's Dealing (DIRS).
2024-11-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.